Therefore, this study investigates whether tumor involvement in TURP specimens, PSA changes following TURP, and post-TURP PSA levels (PSA_TURP) could be used as adjuvant markers to guide a risk-adaptive strategy for localized PC, especially for those who are unable to tolerate the toxicity of curative therapy. The gene discussed is KLK3; the disease is pachyonychia congenita.